Pharma
Treviamet (Sitagliptin + Metformin HCl Tablets)
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Treviamet (Sitagliptin + Metformin HCl Tablets)
Treviamet is a combination antidiabetic medication containing two active ingredients: Sitagliptin and Metformin Hydrochloride. Sitagliptin is a DPP-4 inhibitor that works by increasing levels of incretin hormones, which stimulate insulin release after meals. Metformin is a biguanide that lowers blood sugar by reducing hepatic glucose production and improving insulin sensitivity. This combination is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Common side effects include nausea, diarrhea, and stomach upset.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Antidiabetic combination; Empagliflozin 12.5 mg and Metformin 1000 mg (28 tablets) for Type 2 Diabetes management.